摘要
To the Editor:Palmoplantar pustulosis(PPP)is a chronic recalcitrant disease.Various biologics have been used to successfully treat plaque psoriasis,but their use to treat PPP is limited.Despite their promising effects,biologics such as tumor necrosis factor-α(TNF-α)inhibitors may aggravate or induce PPP.Herein,we report a patient with PPP refractory to the TNF-αinhibitor adalimumab,but successfully treated with the interleukin-17A(IL-17A)inhibitor secukinumab.
基金
National Natural Science Foundation of China(No.81872518)。
